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ABSTRACT
Macrophages have established roles supporting bone formation. Despite their professional phagocytic nature, the role of
macrophage phagocytosis in bone homeostasis is not well understood. Interestingly, apoptosis is a pivotal feature of cellular
regulation and the primary fate of osteoblasts is apoptosis. Efferocytosis (phagocytosis of apoptotic cells) is a key physiologic process
for the homeostasis of many tissues, and is associated with expression of osteoinductive factors. To test effects of macrophage
depletion and compromised phagocytosis on bone, 16-week-old male C57BL/6J mice were treated with trabectedin—a
chemotherapeutic with established anti-macrophage effects. Trabectedin treatment reduced F4/80þ and CD68þ macrophages in
the bone marrow as assessed by flow cytometry, osteal macrophages near the bone surface, and macrophage viability in vitro.
Trabectedin treatment significantly reduced marrow gene expression of key phagocytic factors (Mfge8, Mrc1), and macrophages
from treated mice had a reduced ability to phagocytose apoptotic mimicry beads. Macrophages cultured in vitro and treated with
trabectedin displayed reduced efferocytosis of apoptotic osteoblasts. Moreover, efferocytosis increasedmacrophage osteoinductive
TGF-b production and this increase was inhibited by trabectedin. Long-term (6-week) treatment of 16-week-old C57BL/6J mice with
trabectedin significantly reduced trabecular BV/TV and cortical BMD. Although trabectedin reduced osteoclast numbers in vitro,
osteoclast surface in vivo was not altered. Trabectedin treatment reduced serum P1NP as well as MS/BS and BFR/BS, and inhibited
mineralization and Runx2 gene expression of osteoblast cultures. Finally, intermittent PTH 1-34 (iPTH) treatment was administered in
combinationwith trabectedin, and iPTH increased trabecular bone volume fraction (BV/TV) in trabectedin-treatedmice. Collectively,
the data support a model whereby trabectedin significantly reduces bone mass due to compromised macrophages and
efferocytosis, but also due to direct effects on osteoblasts. This data has immediate clinical relevance in light of increasing use of
trabectedin in oncology. © 2017 American Society for Bone and Mineral Research.
KEY WORDS: EFFEROCYTOSIS; MACROPHAGES; TRABECTEDIN; PARATHYROID HORMONE; OSTEOIMMUNOLOGY
Introduction
Bone not only provides a rigid structure enabling locomotion,but also houses critical physiologic functions such as
hematopoiesis and supports the immune system. The environ-
ment of diverse cells in the bone marrow interact with their
osteoblast and osteoclast neighbors on the bone surface,
regulating bone homeostasis and structure. Myeloid cells are
white blood cells that comprise a large portion (15% to 25%) of
the marrow, and acquire defined roles regulating the develop-
ment, homeostasis, andhealing ofmany tissues. Investigating the
role of myeloid cells in the bone marrow and specifically osteal
macrophages in bone homeostasis was the focus of this study.
Despite the large number of macrophages in bone, their role
supporting bone formation has only recently emerged.(1,2)
Evidence includes reports of depletion of a broad spectrum of
monocyte and macrophage cells under the csf1r promoter
leading to reduced osteoblast activity in vitro and in vivo, and
significantly less bone mass.(3,4) In addition, histologic studies
identified a population of osteal macrophages (also known as
OsteoMacs) that line a majority of bone formation surfaces in
vivo,(3) further linking bone resident macrophages to their
support of bone formation. Interestingly, although macro-
phages (“big-eaters” in Greek) are literally named for their
phagocytic ability, the professional phagocytic role of osteal
macrophages in bone homeostasis has been largely overlooked.
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Macrophages eat a variety of targets including apoptotic cells.
Given that the primary fate of osteoblasts is apoptosis(5,6) and
osteal macrophages are found intimately associated with
osteoblast-lined bone surfaces,(2,3) macrophages may support
bone formation via their clearance of apoptotic bone cells. Yet
the consequence of altered macrophage clearance of apoptotic
osteoblasts is unclear.
Efferocytosis (phagocytosis of apoptotic cells) is an area of
interest that has key physiologic roles in lung homeostasis,(7,8)
atherosclerosis,(9,10) disease states such as systemic lupus
erythematosus,(11) and cancer.(12) In addition to clearing
apoptotic cells and preventing buildup of a toxic microenviron-
ment, efferocytosis also causes macrophage expression of
specific chemoattractant and stimulatory cytokines such as
TGF-b(13,14) and CCL-2.(15) Recent data strongly suggests a role
for efferocytosis in bone homeostasis. For example, although
broad depletion of monocytes and macrophages decreased
bone mass, an experimental model with increased phagocytic
CD68þ cells had increased bonemass.(4) In addition, increases in
CD163þ cells and efferocytic gene expression (eg, MFG-E8,
MRC1, ARG1) further suggested that changes in macrophage
efferocytosis were related to the bone phenotype. However,
efferocytosis was not directly assessed in that study. Therefore,
the purpose of this study was to examine the role of
macrophages and their efferocytic function in bone biology.
Specifically, we determined whether a model with decreased
phagocytic CD68þ macrophages and reduced efferocytosis
would result in low bone mass. In the present study, macro-
phages were manipulated via the chemotherapeutic agent
trabectedin, which has been shown to selectively inhibit
macrophages.(16) There is also strong clinical motivation for
this work. Although trabectedin was recently approved by the
US Food and Drug Administration (FDA) for use in patients with
soft-tissue sarcomas, and is presently in multiple clinical trials for
additional forms of cancer,(17) its impact on bone is unknown.
Materials and Methods
Animals
All animal experiments were performedwith the approval of the
University of Michigan Committee for the Use and Care of
Animals. Skeletally mature 16-week-old C57BL/6J male mice
(Jackson Laboratory, Bar Harbor, ME, USA) were used unless
otherwise noted in long-term and short-term treatment
regimens, housed three to five per cage in specific pathogen
free (SPF) conditions, fed 5001 chow (Purina), randomized to
groups, and given IDs for blinding during subsequent analyses.
Trabectedin (Yondelis, PharmaMar, Madrid, Spain) was dissolved
in dimethyl sulfoxide (DMSO) at a stock concentration of 1mM,
and stored at –20°C until use. A long-term (6-week) treatment
regimen was used where animals were administered trabecte-
din (0.15mg/kg, i.v. tail vein, biweekly) or vehicle (0.9% saline
and DMSO) under isoflurane. Trabectedin treatments were
blinded to the injector. Because local tail vein injection site
reactions can occur with trabectedin, 14 animals were allocated
to the long-term trabectedin group, three of which were
euthanized early due to local tail vein injection site reactions
resulting in n¼ 11/group. A short-term treatment regimen (1
week) included a single injection of trabectedin (0.15mg/kg, tail
vein) or vehicle given at 16 weeks of age with n¼ 8/group. To
assess the effect of anabolic intermittent parathyroid hormone
1-34 (iPTH) onmacrophages and osteoblasts in conjunctionwith
trabectedin, mice were treated with iPTH (50mg/kg body
weight, daily) or vehicle (0.9% saline [Veh]) with or without
trabectedin (0.15mg/kg, i.v. tail vein and retro-orbital, biweekly)
for 6 weeks with n¼ 10 to 13/group. One Veh/iPTH mouse did
not recover after isoflurane and vehicle i.v. injection, leaving
Veh/Veh n¼ 10, Veh/iPTH n¼ 9, Trabectedin/Veh n¼ 12,
Trabectedin/iPTH n¼ 13. Trabectedin treatment began 3 days
prior to iPTH to ensure trabectedin effects at the onset of iPTH.
For dynamic histomorphometry analysis, a cohort of animals
(n¼ 12/group) were treated with trabectedin or vehicle
(0.15mg/kg), given calcein (30mg/kg) injections 5 and 2 days
before euthanasia, and euthanized 1 week after the single
trabectedin injection.
Blood and serum ELISAs
Blood was harvested at euthanasia by intracardiac puncture,
allowed to coagulate for several hours at room temperature,
serum separated by centrifugation, stored at –80°C, and
P1NP and tartrate-resistant acid phosphatase 5b (TRAcP5b)
(Immunodiagnostics Systems, The Boldons, UK) were measured
using enzyme immunoassays.
Flow cytometry
Marrow was flushed from the femur of mice immediately after
euthanasia in FACS buffer (PBS with 2% FBS, 0.5mM EDTA). Each
stain included 1 106 cells with anti-mouse F4/80 (BioLegend,
San Diego, CA, USA, or Abcam, Cambridge, MA, USA; A3-1) or
anti-mouse CD68 (BioLegend; FA-11). Isotype controls were
used to confirm specificity. Flow cytometry was performed using
a FACS AriaIII (BD Biosciences, San Jose, CA, USA).
Micro–computed tomography
Dissected and fixed (10% Neutral Buffered Formalin  NBF,
24hrs) tibiae were scanned by ex-vivo micro–computed
tomography (mCT) at a 12-mm voxel size (Scanco mCT-100;
Scanco Medical AG, Br€uttisellen, Switzerland) and assessed
following established guidelines.(18) Trabecular bone parame-
ters weremeasured over 40 slices (480mm) immediately distal to
the proximal growth plate by manually outlining the endocort-
ical border and thresholding at 180mg/cm3. Cortical bone
parameters were measured over 30 slices (360mm) extending
distally from a location 3mm proximal to the tibia-fibula
junction. A threshold of 280mg/cm3 was used for cortical bone.
Histomorphometry and dynamic histomorphometry
Tibias were fixed in 10% neutral buffered formalin (NBF), stored
in 70% ETOH, decalcified in 14% ethylenediaminetetraacetic
acid (EDTA), embedded in paraffin, and sectioned at 5 mm. A
central slice of the proximal tibia was stained by H&E and bone
morphometry was analyzed using OsteoMeasure software
(OsteoMetrics, Decatur, GA, USA) and an Olympus (Tokyo,
Japan) microscope for bone area/tissue area (BA/TA), Tb.Th, and
Tb.N.(19,20) The ROI began 200mm distal to the proximal
growth plate, extended 1215mm distally, and was 1150mm
wide (or 50mm from endocortical surface). An adjacent section
was stained for tartrate resistant acid phosphatase (TRAP; Sigma,
St. Louis, MO, USA; 387A) and hematoxylin. Using the ROI
described above, osteoclast surface (Oc.S), bone surface (BS),
and number of osteoclasts were quantified.(19) Similarly, osteal
macrophages were quantified by immunostaining of adjacent
paraffin sections for F4/80 (Abcam; ab6640; Anti-Rat HRP-DAB
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Kit; R&D Systems, Minneapolis, MN, USA) and identified by their
proximity of within three cell diameters of the bone surface.(21)
Osteal macrophage number normalized to tissue area and bone
surface were quantified. Dynamic histomorphometry was
performed in 16-week-old C57BL/6J male mice treated with
vehicle or trabectedin (0.15mg/kg i.v., n¼ 12/group) and given
calcein injections 5 days and 2 days before euthanasia at
17 weeks of age. In brief, tibias were cut cross-sectionally, placed
in 10% phosphate-buffered formalin for 48 hours, dehydrated in
ethanol, and embedded undecalcified in methyl methacrylate.
The proximal tibias were sectioned longitudinally at 8mm
thicknesses with a Leica/Jung 2065 microtome and used to
measure fluorochrome-based indices of bone formation. The
ROI began 0.4mm distal to the growth plate and excluded
the primary spongiosa and cancellous bone within 0.1mm of
the endocortical surfaces, including a 1.2mm (width) by 3.6mm
(length) area. Mineral apposition rate (MAR), SL (Single Label),
DL (Double Label), mineralizing surface (MS/BS), and bone
formation rate per unit of bone surface (BFR/BS) were
enumerated or calculated following recommendations of the
Histomorphometry Nomenclature Committee of the American
Society of Bone and Mineral Research.(20)
RT-PCR
Bone marrow was flushed with TRIzol from the femur of mice
treated with trabectedin or vehicle for 1 week, and RNA was
isolated. For cell culture experiments, RNA was isolated with the
RNeasy system (Qiagen, Valencia, CA, USA). In each case, RNA
was quantified (Nanodrop, Thermo Fisher Scientific, Waltham,
Fig. 1. Trabectedin treatment inhibits macrophages. (A) Male 16-week-old C57BL/6J mice treated with trabectedin (Tbdn) or vehicle (Veh) for 6 weeks
(0.15mg/kg, three biweekly injections, n¼ 9 to 13/group). After marrow extraction, cells were stained for F4/80 (B) and phagocytic marker CD68 (C), and
analyzed by flow cytometry, with representative images shown. (D–F) In animals treated for 1 week with trabectedin, tibial paraffin sections of
metaphyseal trabecular bone and stained for F4/80 by immunohistochemistry. Osteal macrophages per tissue area were quantified (E) and
representative images are shown (F) with red arrows denoting examples of osteal macrophages (F4/80þ and within 3 cell diameters of bone surface).
(G, H, J) To confirm a direct effect of trabectedin on macrophages, macrophages (Mf) were expanded from the bone marrow from 4-week-old to
8-week-old C57BL/6J mice with M-CSF, and viability assessed by trypan blue exclusion after trabectedin treatment. (G, I, K) Similarly, BMSCs from
4-week-old to 8-week-old C57BL/6J mice were expanded with dexamethasone, viability assessed after trabectedin treatment. Data are mean SD.
p< 0.05 versus Veh. Mf¼macrophages; Tbdn¼ trabectedin; Veh¼ vehicle.
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MA,USA) and cDNAgenerated via reverse transcriptase reactions.
cDNA products were amplified and detected with TaqMan Gene
Expression PCR master mix (Applied Biosystems, Foster City, CA,
USA) and TaqMan probes included Mfge8 (Mm00500549_m1),
Mrc1 (Mm01329362_m1), Mertk (Mm00434920_m1), and Runx2
(Mm00501584_m1). Gapdh (Mm99999915_g1) was used as the
reference for bone marrow, and Actb (Mm02619580_g1) was
used for as a reference for in vitro experiments. Real-time PCRwas
analyzedonaViiA7 (AppliedBiosystems, Foster City, CA, USA) and
quantifiedvia the comparative threshold cycle (DDCt)method.(22)
Ex vivo phagocytosis assay
Bone marrow was flushed from the femur of mice 1 week after a
single dose of trabectedin or vehicle and immediately co-
cultured with FITCþ 5-mm-diameter apoptotic-mimicry beads
(Bangs Laboratories, Fishers, IN, USA) with a 1.1 ratio of cells:
beads at 37 °C (4 °C was used as a control) in a flow cytometry
tube. After 5 hours, cells were fixed with 1% formalin on ice for 1
hour, stained for F4/80 (APC), and analyzed by flow cytometry to
assess phagocytosis. To visualize bead internalization and
attachment to macrophages, samples were further analyzed
using ImageStream (EMD Millipore, Billerica, MA, USA).
Efferocytosis of apoptotic osteoblasts in vitro
Primary macrophages were cultured by flushing bone
marrow from the hindlimbs of 4-week-old to 8-week-old
C57BL/6J with macrophage colony stimulating factor (M-CSF,
30 ng/mL; PeproTech, Rocky Hill, NJ, USA) for 1 week, and
750,000 cells were split into each well of a six-well plate as
described.(15) Macrophages attached overnight in a-MEM
media with 5% FBS and 15 ng/mL M-CSF, and subsequently
treated with 2.5nM trabectedin in DMSO or vehicle (DMSO)
for 12 hours in low serum media (0.25% FBS). Prior to co-
culture, osteoblastic MC4 (MC3T3-E1 subclone4)(23) cells were
expanded, stained (DeepRed CellTracker; Thermo Fisher
Scientific, Rockford, IL, USA), induced to apoptosis by
30min of exposure to a UV light source (>90% Trypan
Blueþ), allowed to recover for 2 hours at 37°C, and added in
equal number (1:1) to trabectedin-treated and vehicle-
treated macrophages as described.(15) After 1 hour, the
efferocytic co-culture was stopped by fixation with 1%
formalin, cells were harvested, and macrophages were
stained green (FITC, F4/80). Efferocytosis was assessed as
the percentage of double positive FITC macrophages and
Deep Red–stained apoptotic MC4 cells by flow cytometry.
Fig. 2. In vivo trabectedin treatment reduces phagocytic ability of macrophages. (A) Sixteen-week-oldmale C57BL/6J mice were treated for 1 week with
trabectedin (0.15mg/kg) or vehicle (Veh). Marrow was extracted and mRNA isolated to assess gene expression. (B) Significantly decreased expression of
Mfge8 (linker protein that facilitates efferocytosis) and Mrc1 (marker of alternatively activated efferocytic macrophages), and unaltered levels of Mertk
(protein that facilitates efferocytosis). (C) Fresh bone marrow cells were isolated from 16-week-old male C57BL/6J mice treated for 1 week with
trabectedin (0.15mg/kg) or Veh, and immediately co-culturedwith FITCþ apoptoticmimicry beads. After 5 hours of phagocytosis, co-cultures were fixed,
macrophages were stained for F4/80 (D), and the percent of F4/80þmacrophages that ingested or were attached to a FITCþ bead was assessed via flow
cytometry (E). Trabectedin significantly reduced phagocytosis within the F4/80 macrophage population (F). n¼ 8/group. Data are mean SD. p< 0.05
versus Veh. Veh¼ vehicle; WL¼White Light.
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TGF-b secretion by efferocytic macrophages
Macrophages treated with vehicle or trabectedin were co-cultured
with apoptoticMC4 cells as described in previousmethods section.
After 18 hours of co-culture, supernatantswere harvested to assess
secreted TGF-b by macrophages in response to efferocytosis.
Supernatants were exposed to acid to convert to active TGF-b, and
thenactiveTGF-bwasassessedwitha commercially available ELISA
(R&D Systems). The a-MEM media supplemented with 0.25% FBS
contained undetectable levels of TGF-b (data not shown).
Viability of macrophages, MC4 cells, calvarial osteoblasts,
and bone marrow stromal cells
Macrophages from 4-week-old to 8-week-old C57BL/6J mice
were expandedwith M-CSF and plated at 750,000 per well in six-
well tissue culture plates as described in previous “Efferocytosis
of apoptotic osteoblasts in vitro” methods section. MC4 cells,
and bone marrow stromal cells (BMSCs) isolated from 4-week-
old to 8-week-old C57BL/6J mice and expanded with 10nM
dexamethasone, were cultured as described. Primary calvarial
osteoblasts were isolated from 4-day-old to 10-day-old C57BL/6J
mice per published protocols.(24) BMSCs, MC4 cells, and
macrophages were treated with vehicle (DMSO) or trabectedin.
Cells were removed from the plate with 0.25% trypsin
immediately after treatment, or after being returned to normal
a-MEM with 10% FBS for 4 days, and viability and cell number
were assessed by trypan blue staining with a hemocytometer.
Osteoclast formation and resorption assays
Marrow was flushed from the long bones of 4-week-old to
8-week-old C57BL/6J mice into a 100-mm dish in a-MEM with
10% FBS and 1% penicillin-streptomycin-glutamine (PSG)
overnight. The next day, suspension cells were re-plated in
new 100-mm Petri culture plastic dishes with 30 ng/mL of
M-CSF, and expanded for 4 to 5 days until confluent. Cells were
then split with ice-cold PBS containing 1mM EDTA and re-plated
at 60,000/cm2 in 48-well or 96-well plates with 30 ng/mL of
M-CSF and 50 ng/mL of murine RANKL (PeproTech, Rocky Hill,
Fig. 3. Reduced macrophage efferocytosis with trabectedin in vitro. (A) Marrow was extracted from 4-week-old to 8-week-old C57BL/6J mice, and
macrophages expanded with M-CSF for 1 week. MC4 cells were stained red via DeepRedCell tracker dye, induced to apoptosis by UV light, and
subsequently added to macrophages that were treated with trabectedin or vehicle. Macrophages were subsequently stained for F4/80 with an FITC
fluorophore. (B) Efferocytosis was assessed by double-positive F4/80 and apoptotic MC4 cells, and efferocytosis was reduced by trabectedin
pretreatment at a dose (2.5nM, 12 hours) that did not affect (C) macrophage viability (n¼ 6 to 9/group). (D) Macrophages secreted significantly more
osteoinductive TGF-bwith efferocytosis, and this increase was inhibited by trabectedin (10nM, 24 hours) in vitro as assessed by ELISA (n¼ 3/group). Data
are mean SD. p< 0.05 versus Veh. Veh¼ vehicle.
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NJ, USA). Once multinucleated osteoclasts began forming
(4 to 5 days), wells were treated with trabectedin or vehicle.
Cells were subsequently fixed with 10% formalin, stained for
TRAP (Sigma, St. Louis, MO, USA; 387A), and enumerated. To
assess effects of trabectedin on resorption, similar experiments
were carried out on 96-well Corning Osteo Assay plates (Sigma,
St. Louis, MO, USA) coated with hydroxyapatite, and hydroxy-
apatite dissolution was assessed. Macrophages were first grown
as described above in separate plates with M-CSF and then
similarly split in equal number into wells of Corning Osteo Assay
plates and RANKL added. After osteoclastogenesis on D3-D4 in
the Corning Osteo Assay plate, cells were treated with
trabectedin at specified doses, replaced with normal osteoclast
media for an additional 24 hours after treatment, and resorption
area was quantified as the percent of white area.
Osteoblast mineralization and gene expression
Primary calvarial osteoblasts were isolated from 4-day-old to
10-day-oldC57BL/6Jmiceper publishedprotocols,(24) and cultured
in a-MEM with 10% FBS and 1% PSG. Once cells reached
confluence (day 0), media was supplemented with 50mM ascorbic
acid for gene expression or 50mM ascorbic acid plus 10mM
b-glycerol phosphate for mineralization assays with every media
change. MC4 cells were grown under identical conditions.
Osteoblasts used for gene expression were treated from day 4 to
day 5 with varying doses of trabectedin and RNA was collected on
day 5. Osteoblasts assayed formineralizationwere similarly treated
fromday 4 to day 5, subsequently replacedwithmedia supplanted
with 50mM ascorbic acid plus 10mM b-glycerol phosphate and
allowed to mineralize to day 14 (MC4) or day 21 (calvarial
osteoblasts). Von Kossa staining was performed as described.(25)
Statistical analysis
Student’s t test, or paired t test, was used where appropriate and
after normality was assessed. The trabectedin and iPTH in vivo
data with 2 2 experimental design was analyzed by two-way
ANOVA, and least significant difference (LSD) post hoc test. Power
analysis calculations assuming 5% type I error indicated that
n¼ 8/group had a 85% chance to detect a difference between
means based on 1.5 standard deviations between groups—
assumptions based on historical data. Values of p <0.05 were
considered significant, and data are shown as mean SD.
Results
Trabectedin inhibits macrophages and phagocytic cells
in vivo and in vitro
Trabectedin treatment in vivo reduced F4/80þ macrophages
in the bone marrow by 16% compared to vehicle when
assessed after 6 weeks of treatment (Fig. 1A, B). In addition,
Fig. 4. Trabectedin reduces trabecular and cortical bone properties. (A) Long-term treatment regimen (6weeks, 0.15mg/kg, 3) with trabectedin (Tbdn)
or vehicle (Veh) was used to assess whole-bone changes the proximal tibia of 16-week-old male C57BL/6J mice. (B–E) Representative mCT and H&E
images show reduced trabecular bone mass with treatment. (F, G) Quantification of mCT revealed a decrease in trabecular BV/TV due to significantly
reduced trabecular number. (H) Trabectedin effects were also assessed in cortical bone of the diaphyseal tibia. (I, J) Representative mCT images show
decreased cortical bone, including reduced cortical thickness (K) and BMD (L). n¼ 11/group. Data are mean SD. p< 0.05 versus Veh.
Tbdn¼ trabectedin; Veh¼ vehicle.
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phagocytic CD68þ cells in the bone marrow were reduced
by 23% with trabectedin treatment (Fig. 1C). Osteal macro-
phages, identified as F4/80þ cells near the bone surface,
were significantly reduced (–39%) per tissue area (Fig. 1D–F)
as well as per bone surface (data not shown).
In vitro experiments confirmed trabectedin directly inhibits
macrophages. Primary murine macrophages grown with
M-CSF for 1 week were treated with trabectedin and viability
assessed by trypan blue exclusion. Treatment for 24 hours
with 10nM trabectedin significantly decreased macrophage
viability by 43%, and 24 hours with 2.5nM trabectedin
decreased macrophage viability by 17% (Fig. 1G, H, J). BMSCs
expanded from marrow with dexamethasone were treated
with identical doses of trabectedin and no significant
difference in viability was observed (Fig. 1I, K), indicating
relative specificity to the myeloid lineage.
Fig. 5. Trabectedin reduces markers for bone formation and mineralization. (A) Short-term (1 week, single injection 0.15mg/kg, n¼ 8/group) or long-
term (6weeks, 3 biweekly injections, 0.15mg/kg, n¼ 11/group) with trabectedin or vehicle (Veh) reduced serumP1NP, amarker of bone formation. (D–F)
A cohort (n¼ 12/group) of mice were treated with trabectedin or vehicle for 1 week as shown in A and given calcein injections 5 or 2 days prior to
euthanasia to facilitate dynamic histomorphometric analysis of tibial trabecular bone. Trabectedin treatment significantly reduced BFR/BS and MS/BS,
but not MAR. (G, I) To assess direct effects of trabectedin on osteoblasts, calvarial osteoblasts were isolated from 4-day-old to 10-day-old C57BL/6J mice
and treated with trabectedin from days 4 to 5, replaced with normal mineralization media with ascorbic acid and beta-glycerophosphate until day 21,
and stained for Von Kossa (n¼ 6/group). Representative images are shown. (H, J) The same treatment strategy as in G, Iwas used in theMC4 cell line, and
stained via Von Kossa at day 14 (n¼ 6/group). (K, L) To assess effects of trabectedin on osteoblast gene expression, both calvarial osteoblasts and MC4
cells were treatedwith trabectedin fromdays 4 to 5 and assessed by RT-PCR for relative Runx2 expression (n¼ 6/group). p< 0.05 relative to Veh. Data are
mean SD. Tx¼ treatment; Veh¼ vehicle.
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Trabectedin leads to reduced efferocytic gene
expression and reduced macrophage efferocytosis
One week after a single injection of trabectedin, total gene
expression in the marrow showed reduced levels of key
macrophage efferocytosis mediators Mfge8 (–48%) and Mrc1
(–38%) (Fig. 2A, B). To assess functional changes in
phagocytosis, marrows harvested from mice 1 week after a
single injection of trabectedin were immediately co-cultured
with FITCþ apoptotic mimicry beads. The co-culture was
stained for F4/80 and flow cytometry analysis revealed a
significant decrease (–28%) in phagocytosis as indicated by
the %F4/80þBeadþ cells (Fig. 2C–F). In vitro experiments
extended this finding using apoptotic osteoblasts as the
prey. Apoptotic osteoblastic MC4 cells were added in co-
culture to primary macrophages that were treated with
trabectedin. Trabectedin treatment of macrophages reduced
their efferocytosis of apoptotic MC4 osteoblasts as indicated
by significantly reduced double-positive (%F4/80þ apMC4þ)
cells without significant compromise in viability (Fig. 3A–C).
Macrophage efferocytosis significantly increased secretion of
osteoinductive TGF-b, and this increase was inhibited by
trabectedin in vitro (Fig. 3D).
Trabectedin significantly reduces trabecular and cortical
bone mass
The bone phenotype was evaluated in mice treated with
trabectedin for 6 weeks (three biweekly administrations). In
the proximal tibia, BV/TV was significantly reduced (–52%)
compared to vehicle controls as measured by mCT (Fig. 4A–F).
Reductions in BV/TV were the result of large decreases in Tb.N
(–21%) (Fig. 4G) and increases in Tb.Sp but no significant
change in Tb.Th (data not shown). Histologic evaluation of the
proximal tibia on H&E-stained sections (Fig. 4D, E) confirmed
the mCT data, and showed an 84% reduction in BA/TA (data
not shown). In cortical bone of the diaphyseal tibia, similar
findings of decreased bone mass were observed, evidenced by
reduced cortical thickness (–9%) and cortical BMD (–6%)
(Fig. 4H–L). Ct.Ar/Tt.Ar was significantly reduced (–7%), Ct.Ar
trended less (–9%, p¼ 0.06), and Tt.Ar was unchanged
(p¼ 0.72) (data not shown).
Fig. 6. Analysis of trabectedin effects on osteoclasts. (A,B) Both short-term (1 week, single injection 0.15mg/kg, n¼ 8/group) or long-term (6 weeks,
3 biweekly injections 0.15mg/kg, n¼ 11/group) trabectedin treatment regimens were performed and OcS/BS was assessed by TRAP staining of a central
slice of the proximal tibia. (C, D) In these same mice, serum TRAcP5b was quantified. (E) To assess direct effects of trabectedin on osteoclast number in
vitro, osteoclasts were cultured from the marrow of 4-week-old to 8-week-old C57BL/6J mice with M-CSF and RANKL. After osteoclastogenesis on
days 4 to 5, cells were treated with trabectedin at specified doses, stained for TRAP, and enumerated (n¼ 6/group). Representative images are shown
beneath. (F) To assess functional changes in resorption with trabectedin, osteoclasts were grown on Corning Osteo Assay plates under identical
conditions, treatedwith trabectedin on days 4 to 5, replacedwith normal osteoclastmedia for an additional 24 hours after treatment, and resorption area
was quantified as the percent of white area. Representative images are shown. p< 0.05 relative to Veh. Data are mean SD. Veh¼ vehicle; OcS/BS¼
osteoclast surface per bone surface.
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Trabectedin reduces bone formation, and directly
inhibits osteoblast gene expression and mineralization in
vitro
Serum P1NP, a marker of bone formation, was significantly
decreased (–27%) 1 week after a single trabectedin injection, and
trended toward a decrease (–26%, p¼ 0.086) after 6 weeks of
trabectedin treatment (Fig. 5A–C). Dynamic histomorphometry
of tibial trabecular bone 1 week after a single of injection of
trabectedin showed significantly reduced MS/BS (–42%) and
BFR/BS (–48%) (Fig. 5D, E). The remaining areas of dual label after
trabectedin treatment showed no significant change in MAR
relative to vehicle (Fig. 5D–F). To determine if reductions in bone
formation were related to direct effects of trabectedin on
osteoblastic cells, osteoblast in vitro assays were performed.
Primary calvarial osteoblasts were cultured in mineralization
media, and treated with trabectedin from day 4 to day 5, and
subsequently allowed to mineralize in trabectedin-free minerali-
zation media to day 21. At day 21, Von Kossa staining revealed
significantly less mineralization in calvarial osteoblasts treated
with trabectedin (Fig. 5G, I). Runx2 gene expression was also
reduced in primary calvarial osteoblast cells using the same
treatment strategy and assessing acute gene expression on day 5
in the highest trabectedin dose (Fig. 5K). Both of these findings in
primary calvarial osteoblasts were corroborated by parallel
experiments performed in the MC4 cell line (Fig. 5H, J, L). In
MC4 cells, Runx2 gene expression was significantly reduced at
day 5 (Fig. 5I), andmineralizationwas significantly lower at day 14
with trabectedin treatment (Fig. 5E, G). Using an identical
treatment protocol in both calvarial and MC4 osteoblasts, but
assessing cell viability, it was found that after 24 hours treatment
did not significantly impact osteoblast viability (Supporting
Fig. 1A). However, treatment for 24 hours, and then replacement
with normal media for 4 additional days led to significantly
compromised osteoblast cell number by day 5 (Supporting
Fig. 1B).
Trabectedin effects on osteoclasts
Histologic osteoclast analysis by TRAP staining in sections of
the proximal tibia revealed no change in Oc.S/BS 1week after a
single injection of trabectedin, or after 6 weeks of biweekly
treatment (Fig. 6A, B). Similar histologic TRAP staining data was
observed for N.Oc/BS (data not shown). Serum analysis of
TRAcP5b showed no change after 6 weeks of treatment, but
did show a significant decrease 1 week after a single injection
(–38%) (Fig. 6C, D). To assess direct effects of trabectedin on
osteoclasts, primary murine osteoclasts were differentiated
with RANKL and treated with trabectedin. After cells
differentiated into osteoclasts on approximately day 4 of
culture, trabectedin treatment decreased the total number of
multinucleated TRAPþ cells by 24% (Fig. 6E). Detailed analysis
revealed that while trabectedin decreased the number of
smaller osteoclasts with dense cytoplasm, large osteoclasts
were similar in number with treatment but appeared to have
less dense cytoplasm with trabectedin treatment. To assess
functional effects of trabectedin on bone resorption in vitro,
osteoclasts were cultured on hydroxyapatite coated plates.
After osteoclasts began to form on approximately day 4 of
culture, wells were treated with trabectedin for 24 hours,
subsequently replaced with normal osteoclast media for 24
additional hours, and assessed for resorption pits. No
significant change in resorption pit area was detected with
trabectedin treatment (Fig. 6F).
Anabolic PTH treatment in combination with trabectedin
Anabolic treatmentwith intermittent PTH1-34 (iPTH) significantly
increased tibial trabecular BV/TV due to increases in Tb.N in
non–trabectedin-treated mice (Fig. 7A–C). Similar to Fig. 4,
6 weeks of trabectedin treatment reduced trabecular BV/TV due
to a reduction in Tb.N. iPTH treatment significantly increased BV/
TV in trabectedin-treatedmice due to significant changes in Tb.N.
However, Tb.N in mice treated with both iPTH and trabectedin
was significantly less than untreated Veh/Veh controls (Fig. 7C).
BV/TV in mice receiving both trabectedin and iPTH was not
significantly different than untreated control mice.
Fig. 7. Anabolic PTH partially rescues trabectedin treatment effects. (A)
Male 16-week-old C57BL/6Jmice were treated in a 2 2 study design for
6weekswith either trabectedin or its vehicle control, and/or intermittent
PTH 1-34 (iPTH) or its vehicle control (n¼ 9 to 13/group). To ensure
trabectedin was having biologic activity at the commencement of
anabolic therapy, iPTH was started 3 days after the first trabectedin
injection. (B) Trabectedin significantly reduced trabecular tibial BV/TV,
iPTH increased BV/TV, and iPTHwas able to increase BV/TV in trabectedin
treated mice. (C) Changes in BV/TV were largely due to changes in Tb.N.
On an absolute level, untreated vehicle control mice had a greater Tb.N
than mice treated with both trabectedin and iPTH, suggesting iPTH did
not completely rescue the trabectedin phenotype. p< 0.05 versus
respective vehicle. #p< 0.05 versus vehicle/vehicle. Data are mean SD.
Veh¼ vehicle.
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Discussion
This study focused on macrophage contributions to skeletal
homeostasis and adds new data to the field of osteoimmunol-
ogy. Although significant contributions have been made that
show the effect of macrophage number on bone, data in this
study extends the field by examining functional changes in
macrophage efferocytosis, thereby highlighting a new mecha-
nism by which macrophages impact bone mass. The results also
have immediate clinical relevance as trabectedin is currently
administered to patients for the treatment of cancer,(17) with no
information about the impact on the skeleton. Thus, the data
presented in this study has immediate implications for patients
receiving trabectedin treatment.
The results of this study add to a growing body of literature
highlighting the impact of osteal macrophages on bone
formation and bone mass. Previously, data found an associa-
tion between elevated phagocytic CD68þ cells, increased
levels of efferocytic genes, and increased bone mass.(4)
Because efferocytosis was not directly assessed, a central
purpose of the present study was to determine whether a
model with reduced CD68þ cells and efferocytosis would have
an associated decrease in bone mass. Indeed, trabectedin
treatment in mice reduced phagocytic CD68þ macrophages
and decreased bone mass. Importantly, we extended the
investigation of decreased efferocytic gene expression and
directly assayed changes in phagocytosis and efferocytosis
with trabectedin. Data show that F4/80þcells were less able to
phagocytose apoptotic mimicry beads, suggesting that the
macrophages were not only fewer in number but also less
functional. This data was corroborated by in vitro studies
showing that trabectedin-treated macrophages were less able
to phagocytose apoptotic osteoblasts. Of note, macrophages
efferocytosing apoptotic osteoblasts secreted significantly
more TGF-b, a well-characterized osteoinductive factor,
suggesting a functional consequence of efferocytosis. This
increase was inhibited by macrophage pretreatment with
trabectedin. We note that our data do not prove that
efferocytosis and macrophage-derived TGF-b are responsible
for bone forming effects, and it may be that apoptotic cell
clearance itself is responsible for a positive impact of
macrophage efferocytosis on bone. Collectively, these data
supports a model whereby macrophages promote bone
homeostasis in part by their efferocytic function.
In addition to effects on macrophages, we also observed
effects of trabectedin on bone formation in vivo as well as direct
effects on osteoblasts in vitro. The in vivo serummarker of bone
formation, P1NP, showed reduced levels with trabectedin
treatment. Similarly, dynamic histomorphometry of metaphy-
seal tibial trabecular bone also showed reduced bone formation
as evidenced by significantly lower MS/BS and BFR/BS with
trabectedin treatment. One possibility to explain reduced serum
P1NP and bone formation in vivo is that it is an indirect effect of
inhibiting macrophages(4,26) and compromising efferocytosis.
However, to determine if trabectedin may also have a direct
effect on osteoblasts, we treated primary calvarial, and MC4
osteoblasts in vitro with trabectedin. Our data showed that
trabectedin inhibited mineralization of both calvarial osteo-
blasts, and MC3T3 (subclone 4) cells in vitro. Moreover, this
inhibition of mineralization was corroborated by reduced Runx2
gene expression in both osteoblast cell types. Although this data
demonstrates a direct effect of trabectedin on osteoblasts,
the mechanism underlying the data is unclear. We note that
mineralization effects on trabectedin are greater in magnitude
than effects on Runx2, suggesting that mineralization
effects may also be due to general toxicity to osteoblasts
(Supporting Fig. 1). Trabectedin interacts with TNF-related
apoptosis-inducing ligand (TRAIL), which mediates its mono-
cytic cell inhibition. TRAIL receptors are present on osteoblasts,
and may regulate cell death under certain conditions.(27–29)
Other possibilities include that trabectedin can bind to the DNA
minor groove and inhibit FUS/CHOP (Fused in Sarcoma/C/EBP
homologous protein) fusion proteins that support osteo-
blasts,(30,31) and cells deficient in homologous recombination
are particularly sensitive to trabectedin effects. Regardless of the
mechanism, trabectedin did appear to directly influence
osteoblasts, even though its effect on cell viability was greater
in macrophages than BSMCs.
Trabectedin effects on osteoclasts were more varied.
Trabectedin treatment of osteoclasts in vitro showed decreased
osteoclast number after a short-term treatment period.
Although serum TRAcP5b was reduced in vivo 1 week after a
single injection of trabectedin, it was not significantly altered
after 6 weeks of trabectedin treatment. Most importantly,
histologic analysis of osteoclasts on the trabecular bone surface
revealed no significant difference or trend after 1 week or
6 weeks of trabectedin treatment. That trabectedin is capable of
directly effecting osteoclasts is not surprising given its already
established impact on macrophages. Indeed, osteoclasts are
susceptible to TRAIL-mediated apoptosis.(32,33) However, the in
vivo analyses of osteoclasts on the bone surface showed no
significant change. It may be that that analysis of osteoclast
surface at time points closer to the injection of trabectedin
(<1 week) would show a difference and align with observed in
vitro effects. We note that previous analysis of osteoclast on the
bone surface in models of macrophage depletion such as the
MAFIA (Macrophage Fas-Induced apoptosis) and clodronate
models similarly did not show a significant difference.(4) This
may collectively suggest that osteoclasts are a prioritized and
conserved differentiation pathway of the myeloid lineage, or
have the ability to quickly reconstitute.
The results of this work have immediate clinical relevance to
patients currently receiving trabectedin for a variety of sarcomas.
In particular, these patientsmaybe at increased risk of fracture on
account of reducedbonemass.Moreover, trabectedin is currently
beingexplored for the treatmentofbreast andprostate cancer,(17)
which preferentially metastasize to the skeleton. Given that bone
cells have been shown to play a role regulating skeletal
metastasis,(34) and that trabectedin modulates bone cells and
the bone microenvironment, it will be important to consider if
potential trabectedin effects on metastasis are due to altering
bone cells in addition to directly inhibiting tumor cells.
In this study, we observed that iPTH was effective at
increasing trabecular bone mass in trabectedin-treated mice.
This data has several implications. First, it may generally suggest
that an anabolic strategy may be an effective therapeutic option
to increase bone mass in patients receiving trabectedin.
Although iPTH is not available for use in cancer patients, other
anabolic bone treatments are in clinical trials.(35) Prior data
suggest that iPTH anabolismmay be regulated by macrophages
and efferocytosis(4,36); however, the data presented here suggest
that partially inhibiting macrophages and efferocytosis with
trabectedin does not inhibit the anabolic actions of PTH. It is
possible that inhibiting macrophages and efferocytosis by a
greater magnitude may further compromise PTH anabolic
effects.
Journal of Bone and Mineral Research TRABECTEDIN: BONE MASS, OSTEOBLASTS, AND MACROPHAGE EFFEROCYTOSIS 2125
Finally, there are several limitations to this study. First, all
experiments were carried out in noncancerous models to
assess the effect of macrophages and efferocytosis on bone
during normal homeostasis. Thus, the results of this study
may not directly model a cancer patient receiving trabecte-
din. An additional limitation is that experiments in this study
were performed in male mice, and therefore results may
differ in females. Finally, results focused on the appendicular
skeleton, and trabectedin effects may differ in axial skeletal
sites.
In summary, this study adds new data regarding the role of
macrophages and efferocytosis within the bone microenviron-
ment. Importantly, it suggests that in addition to macrophage
number, the efferocytic function of macrophages in the bone
microenvironment may also regulate bone homeostasis. In
addition, because patients are currently receiving trabectedin
but the bone phenotype of trabectedin has not been previously
described, the data in this study has immediate clinical
relevance.
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